| 3.62 3.62 (0.28%) | 04-20 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 5.02 |
1-year : | 6.06 |
| Resists | First : | 4.3 |
Second : | 5.19 |
| Pivot price | 3.28 |
|||
| Supports | First : | 2.87 | Second : | 2.38 |
| MAs | MA(5) : | 3.32 |
MA(20) : | 3.38 |
| MA(100) : | 1.97 |
MA(250) : | 1.48 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 59.3 |
D(3) : | 40.5 |
| RSI | RSI(14): 57.2 |
|||
| 52-week | High : | 6.9 | Low : | 1 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ANTX ] has closed below upper band by 9.5%. Bollinger Bands are 34.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.67 - 3.68 | 3.68 - 3.7 |
| Low: | 3.42 - 3.44 | 3.44 - 3.46 |
| Close: | 3.59 - 3.62 | 3.62 - 3.64 |
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Mon, 20 Apr 2026
AN2 Therapeutics (NASDAQ: ANTX) files $80M at‑the‑market offering - Stock Titan
Sat, 18 Apr 2026
12 Health Care Stocks Moving In Friday's Pre-Market Session - Sahm
Fri, 10 Apr 2026
AN2 Therapeutics Launches New $80 Million ATM Program - The Globe and Mail
Fri, 10 Apr 2026
AN2 Therapeutics (ANTX) director receives 1,192-share stock grant as fees - Stock Titan
Thu, 09 Apr 2026
AN2 Therapeutics (NASDAQ: ANTX) launches new $80M at-the-market stock sale - Stock Titan
Wed, 01 Apr 2026
AN2 Therapeutics (ANTX) Upgraded to Buy: What Does It Mean for the Stock? - Eastern Progress
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 36 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 19.9 (%) |
| Held by Institutions | 51.4 (%) |
| Shares Short | 564 (K) |
| Shares Short P.Month | 58 (K) |
| EPS | -1.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.94 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -31 % |
| Return on Equity (ttm) | -52.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -30 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -3.13 |
| PEG Ratio | 0 |
| Price to Book value | 1.86 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.37 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|